Molecular response assessed by (68)Ga-DOTANOC and survival after (90)Y microsphere therapy in patients with liver metastases from neuroendocrine tumours.
OBJECTIVE
We investigated the prognostic role of (68)Ga-DOTANOC in patients affected by hepatic metastases from neuroendocrine tumours (NET) undergoing (90)Y radioembolization ((90)Y-RE).


METHODS
A group of 15 consecutive patients with unresectable NET liver metastases underwent (68)Ga-DOTANOC PET at baseline and 6 weeks after (90)Y-RE. Molecular response was defined as a reduction of >50% in the tumour-to-spleen ratio (ΔT/S). The patients were divided into two groups (responders with ΔT/S >50% and nonresponders with ΔT/S <50%) Patients were followed up by imaging and laboratory tests every 3 months until death or for at least 36 months following (90)Y-RE. Statistical analysis was performed to identify factors predicting overall survival (OS) and progression-free survival (PFS).


RESULTS
A decrease in T/S ratio was seen in all patients on (68)Ga-DOTANOC PET scans performed after (90)Y-RE. Nine patients were classified as responders and six as nonresponders. The mean OS in all patients was 31.0 months. Responders had a significantly (p < 0.001) longer OS (mean 36.0 ± 2.5 months) and PFS (mean 29.7 ± 3.4 months) than nonresponders. In a multivariate analysis, none of the other examined variables including age, unilobar vs. bilobar locations, bilirubin levels, radiological response or the presence of extrahepatic disease significantly predicted patient outcome.


CONCLUSIONS
Molecular response assessed with (68)Ga-DOTANOC PET might be a useful predictor of survival in patients affected by NET liver metastases treated with (90)Y-RE.
Department of Nuclear Medicine, Santa Maria Goretti Hospital, Via Canova 3, 04100, Latina, Italy. lucfil@hotmail.com.
Luca
L
Filippi
Department of Nuclear Medicine, Sant'Andrea Hospital, via di Grottarossa 1035/1039, 00189, Rome, Italy.
Francesco
F
Scopinaro
Department of Interventional Radiology, Santa Maria Goretti Hospital, Via Canova 3, 04100, Latina, Italy.
Giuseppe
G
Pelle
Department of Interventional Radiology, Santa Maria Goretti Hospital, Via Canova 3, 04100, Latina, Italy.
Roberto
R
Cianni
Department of Nuclear Medicine, Santa Maria Goretti Hospital, Via Canova 3, 04100, Latina, Italy.
Rita
R
Salvatori
Department of Biomedicine and Prevention, University Tor Vergata, Viale Oxford 81, 00133, Rome, Italy.
Orazio
O
Schillaci
Department of Nuclear Medicine, Santa Maria Goretti Hospital, Via Canova 3, 04100, Latina, Italy.
Oreste
O
Bagni
D000368:Aged; D014408:Biomarkers, Tumor; D015331:Cohort Studies; D018572:Disease-Free Survival; D004621:Embolization, Therapeutic; D005260:Female; D005710:Gallium Radioisotopes / Q000737:chemistry*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary*; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D064847:Multimodal Imaging; D009362:Neoplasm Metastasis; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging* / Q000473:pathology*; D015282:Octreotide / Q000031:analogs & derivatives; D009942:Organometallic Compounds / Q000737:chemistry*; D049268:Positron-Emission Tomography; D011379:Prognosis; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D016896:Treatment Outcome; D015019:Yttrium / Q000737:chemistry*
C504894:68Ga-DOTANOC; D014408:Biomarkers, Tumor; D005710:Gallium Radioisotopes; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; D015019:Yttrium; D015282:Octreotide
68Ga-DOTANOC; 90Y-Radioembolization; Neuroendocrine tumours; PET/CT